Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma

被引:8
|
作者
Sanchez Hernandez, Alfredo [1 ]
Jose Juan, Oscar [2 ]
Vidal Martinez, Jose [3 ]
Blanco, Remei [4 ]
Macia, Sonia [5 ]
Esquerdo Galiana, Gaspar [6 ]
Aparisi Aparisi, Francisco [7 ]
Garde Noguera, Javier [8 ]
Catot, Silvia [9 ]
Losa Gaspa, Ferran [10 ]
Garcia-Pinon, Francisco [11 ]
机构
[1] Consorcio Hosp Prov Castellon, Serv Oncol Med, Castellon de La Plana 12003, Spain
[2] Hosp Univ & Politecn La Fe, Med Oncol Serv, Valencia, Spain
[3] Hosp Arnau Vilanova, Serv Anal Clin, Valencia 46015, Spain
[4] Hosp Mutua de Terrassa, Med Oncol Serv, Barcelona 08221, Spain
[5] Hosp Gen Elda, Med Oncol Serv, Alicante 03600, Spain
[6] Clin Benidorm, Med Oncol Serv, Alicante 03501, Spain
[7] Hosp Virgen de los Lirios, Med Oncol Serv, Alicante 03804, Spain
[8] Hosp Arnau Vilanova, Med Oncol Serv, Valencia 46015, Spain
[9] Clin Althaia de Manresa, Med Oncol Serv, Barcelona 08243, Spain
[10] Hosp St Joan dEspi Moises Broggi, Med Oncol Serv, Barcelona 08970, Spain
[11] Hosp Prov Castellon, Fdn Comunidad Valenciana, Castellon de La Plana 12003, Spain
关键词
Circulating endothelial cell; NSCLC; Chemotherapy; PACLITAXEL-CARBOPLATIN; PERIPHERAL-BLOOD; SURROGATE MARKER; CLINICAL-VALUE; CANCER; ANGIOGENESIS; BEVACIZUMAB; PROGENITORS; CISPLATIN; SURVIVAL;
D O I
10.1007/s12094-014-1223-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Circulating endothelial cells (CEC) play an important role in tumor neovascularization and may have prognostic value in cancer patients. This study was designed to investigate the role of CEC as a marker for predicting platinum plus pemetrexed first-line chemotherapy efficacy in advanced non-squamous non-small cell lung cancer (NSCLC). A prospective study was performed whose main objective was to study whether the numbers of CEC at baseline and prior to the second and third cycle of chemotherapy were response predictors. Sixty-nine patients received cisplatin plus pemetrexed, and peripheral blood samples were performed at baseline and after second and third cycle. Separation and CEC count were performed using inmunomagnetic separation (CellSearch). The CEC count in 4 mL of peripheral blood was obtained prior to the first, second, and third cycle of treatment. Baseline levels and evolution of CEC were correlated with response to treatment according to RECIST criteria after three cycles of treatment. Sixty-nine patients were included: 43 (64.2 %) received cisplatin/pemetrexed and 24 (35.8 %) carboplatin/pemetrexed. Range of baseline CEC: 8-965 (mean of 153 cel/4 mL). The results after 3 cycles were: 25 partial responses (36.2 %), 17 cases of stabilization of disease (24.6 %), 16 of progressive disease (23.2 %) and 11 non-evaluables (16 %). No significant relationship between the baseline CEC count and response was found (p value = 0.831). Increase > 50 % between the first and second cycle was correlated significantly with progression disease (p = 0.008). Patients who had a baseline CEC count greater than the mean (> 153 cells/4 mL) showed longer progression-free survival and global survival without statistical significance. In this homogeneous group of patients with NSCLC, there is no correlation between response to treatment and CEC baseline levels. The increase in CEC numbers after the first cycle could be a negative predictive factor.
引用
收藏
页码:281 / 288
页数:8
相关论文
共 50 条
  • [31] A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer
    Afzal, Muhammad Zubair
    Dragnev, Konstantin
    Shirai, Keisuke
    JOURNAL OF THORACIC DISEASE, 2018, 10 (06) : 3575 - 3584
  • [32] RESPONSE RATES TO CARBOPLATIN AND PEMETREXED IN NON-SQUAMOUS NON-SMALL CELL LUNG CANCER - A SINGLE CENTRE AUDIT
    Talbot, Toby L. J.
    Collinson, Matthew P.
    Buscombe, Charlotte
    Pascoe, Susan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1210 - S1210
  • [33] Atezolizumab in non-squamous non-small cell lung cancer
    Akamine, Takaki
    Toyokawa, Gouji
    Tagawa, Tetsuzo
    Seto, Takashi
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3155 - S3159
  • [34] Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid
    Kwok, Wang Chun
    Cheong, Tan Fong
    Chiang, Ka Yan
    Ho, James Chung Man
    Lam, David Chi Leung
    Ip, Mary Sau Man
    Tam, Terence Chi Chun
    LUNG CANCER, 2021, 152 : 15 - 20
  • [35] Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer
    Karayama, Masato
    Inui, Naoki
    Fujisawa, Tomoyuki
    Enomoto, Noriyuki
    Nakamura, Yutaro
    Kuroishi, Shigeki
    Yokomura, Koshi
    Koshimizu, Naoki
    Sato, Masaki
    Toyoshima, Mikio
    Shirai, Toshihiro
    Masuda, Masafumi
    Yamada, Takashi
    Imokawa, Shiro
    Suda, Takafumi
    EUROPEAN JOURNAL OF CANCER, 2016, 58 : 30 - 37
  • [36] Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer
    Xu, Bei
    Liu, Peng
    Yin, Yongmei
    Liu, Ping
    Shu, Yongqian
    BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (08) : 763 - 769
  • [37] The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC)
    Ding, Lingyu
    Liu, Kejun
    Jiang, Zhelong
    Chen, Qi
    Zhou, Ningning
    Liang, Ying
    Gao, Hongfei
    Hong, Xiangchan
    Wu, Haiying
    TUMOR BIOLOGY, 2015, 36 (04) : 2491 - 2499
  • [38] Clinical Study of Pemetrexed as the First-line Treatment in Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer
    Pu Xiaolin
    Wang Jun
    Li Wei
    Lu Binbin
    Wang Zhaoxia
    Yang Min
    Fan Weifei
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2013, 1 (04): : 205 - 209
  • [39] Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer
    Jones, Benjamin S.
    Jerome, Mary S.
    Miley, Deborah
    Jackson, Bradford E.
    DeShazo, Mollie R.
    Reddy, Vishnu V. B.
    Singh, Karan P.
    Brown, Olivia C.
    Robert, Francisco
    LUNG CANCER, 2017, 106 : 125 - 130
  • [40] CLINICAL SIGNIFICANCE OF HYPERPIGMENTATION DUE TO PEMETREXED TREATMENT IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN CHINA
    Hu, Qiong
    Li, Aiwu
    Ren, Shengxiang
    Chen, Xiaoxia
    Gao, Guanghui
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S564 - S564